|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,280,000 |
Market
Cap: |
72.89(M) |
Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,622 |
52
Week Range: |
$2.25 - $7.96 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.6 |
Insider 6 Months : 15.5 |
Insider 3/6 Months : 24.3 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
53,764 |
372,269 |
402,465 |
589,934 |
Total Buy Value |
$200,002 |
$1,031,169 |
$1,176,896 |
$1,938,525 |
Total People Bought |
2 |
7 |
8 |
9 |
Total Buy Transactions |
2 |
9 |
11 |
33 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Salamon Steven A J |
Director |
|
2024-03-19 |
4 |
B |
$3.72 |
$100,001 |
D/D |
26,882 |
1,121,025 |
2.39 |
19% |
|
Aharon Gil |
Director |
|
2024-03-19 |
4 |
B |
$3.72 |
$100,001 |
D/D |
26,882 |
1,069,710 |
2.39 |
19% |
|
Hoffman David L. |
GENL COUNSEL, CCO & SECY |
|
2024-03-19 |
4 |
A |
$3.72 |
$74,999 |
D/D |
20,161 |
74,330 |
|
- |
|
Pennell Sandra |
SVP OF FINANCE, PFO AND PAO |
|
2024-03-19 |
4 |
A |
$3.72 |
$99,997 |
D/D |
26,881 |
61,052 |
|
- |
|
Muir Kevin |
GM INTERVENTIONAL ONCOLOGY |
|
2024-03-19 |
4 |
A |
$3.72 |
$50,001 |
D/D |
13,441 |
18,582 |
|
- |
|
Vukovic Vojo |
CHIEF MEDICAL OFFICER |
|
2024-03-19 |
4 |
A |
$3.72 |
$100,001 |
D/D |
26,882 |
126,882 |
|
- |
|
Michel Gerard J |
CHIEF EXECUTIVE OFFICER |
|
2024-03-19 |
4 |
A |
$3.72 |
$150,002 |
D/D |
40,323 |
302,668 |
|
- |
|
Vukovic Vojo |
Chief Medical Officer |
|
2023-12-12 |
4 |
B |
$3.00 |
$120,000 |
D/D |
40,000 |
100,000 |
2.74 |
63% |
|
Michel Gerard J |
Chief Executive Officer |
|
2023-12-08 |
4 |
B |
$2.94 |
$99,960 |
D/D |
34,000 |
262,345 |
2.81 |
71% |
|
Aharon Gil |
Director |
|
2023-11-17 |
4 |
B |
$2.40 |
$240,410 |
I/I |
100,000 |
1,038,828 |
2.1 |
108% |
|
Pennell Sandra |
SVP of Finance, PFO and PAO |
|
2023-11-17 |
4 |
B |
$2.43 |
$72,900 |
D/D |
30,000 |
30,000 |
2.74 |
108% |
|
Vukovic Vojo |
Chief Medical Officer |
|
2023-11-16 |
4 |
B |
$2.48 |
$148,800 |
D/D |
60,000 |
60,000 |
2.74 |
106% |
|
Hoffman David L. |
See Remarks |
|
2023-11-16 |
4 |
B |
$2.48 |
$99,200 |
D/D |
40,000 |
40,000 |
2.74 |
106% |
|
Purpura John |
Chief Operating Officer |
|
2023-10-13 |
4 |
B |
$3.44 |
$49,897 |
D/D |
14,505 |
41,526 |
2.74 |
25% |
|
Sylvester John Richard |
Director |
|
2023-08-21 |
4 |
B |
$4.80 |
$50,640 |
D/D |
10,550 |
10,550 |
2.39 |
-18% |
|
Michel Gerard J |
Chief Executive Officer |
|
2023-08-18 |
4 |
OE |
$4.50 |
$139,995 |
D/D |
31,110 |
228,345 |
|
- |
|
Michel Gerard J |
Chief Executive Officer |
|
2023-03-29 |
4 |
B |
$4.84 |
$95,087 |
D/D |
19,646 |
197,235 |
2.81 |
-27% |
|
Salamon Steven A J |
Director |
|
2022-12-14 |
4 |
B |
$3.62 |
$55,045 |
D/D |
15,215 |
455,315 |
2.39 |
54% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-12-14 |
4 |
B |
$3.62 |
$55,045 |
I/I |
15,215 |
459,315 |
2.1 |
54% |
|
Michel Gerard J |
Chief Executive Officer |
|
2022-12-13 |
4 |
B |
$2.90 |
$150,003 |
D/D |
51,725 |
177,589 |
2.81 |
54% |
|
Michel Gerard J |
Chief Executive Officer |
|
2022-07-20 |
4 |
B |
$3.98 |
$250,000 |
D/D |
62,814 |
125,864 |
2.81 |
-29% |
|
Purpura John |
Chief Operating Officer |
|
2022-05-16 |
4 |
B |
$4.61 |
$15,213 |
D/D |
3,300 |
27,021 |
2.74 |
-30% |
|
Salamon Steven A J |
Director |
|
2022-05-13 |
4 |
B |
$5.03 |
$25,135 |
I/I |
5,000 |
440,100 |
2.1 |
-32% |
|
Salamon Steven A J |
Director |
|
2022-05-12 |
4 |
B |
$4.90 |
$29,424 |
I/I |
6,000 |
29,424 |
2.1 |
-27% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-19 |
4 |
B |
$6.25 |
$10,000 |
I/I |
1,600 |
433,100 |
2.1 |
-34% |
|
118 Records found
|
|
Page 1 of 5 |
|
|